中文名稱:法貝司瓊 | 英文名稱:Fabesetron |
CAS:129300-27-2 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
產(chǎn)品類別: 抑制劑 | |
貨號: T38692 |
名稱 | Fabesetron |
描述 | Fabesetron (FK1052) is an orally active compound that acts as a dual antagonist, targeting both the 5-HT3 and 5-HT4 receptors. It exhibits efficacy in studying emesis induced by cancer chemotherapy, showing potential for managing both acute and delayed symptoms. |
體內(nèi)活性 | Fabesetron (FK1052) (0.1 mg/kg p.o.) inhibits completely the increases in the colonic transit[1]. FK1052 (100 μg/kg) completely prevents emesis induced by cisplatin (18 mg/kg, i.p.) in Suncus murinus[2]. Animal Model: Male Sprague-Dawley rats weighing 220 to 330 g and male ddy mice weighing 25 to 35 g were used[1]. Dosage: 0.1 mg/kg. Administration: P.O. Result: Significantly caused delay and its degree of inhibition was 33.8 ± 4.8% by 0.1 mg/kg p.o.. Animal Model: Suncus murinus of either sex (>10-week-old; 30-70 g body weight)[2]. Dosage: 1, 10, and 100 μg/kg. Administration: Orally administered 30 min before the injection of cisplatin. Result: Inhibited cisplatininduced emesis in a dose-dependent manner, and no emesis was observed in three animals given the compound at 100 μg/kg. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
關(guān)鍵字 | Fabesetron | FK-1052 | FK1052 | FK 1052 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥9990 |
VIP9年
|
滄州恩科醫(yī)藥科技有限公司
|
2025-02-08 | |
詢價(jià) |
VIP6年
|
湖北惠擇普醫(yī)藥科技有限公司
|
2025-01-05 | |
¥800 |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2025-02-08 |